Sex-related differences in response to aspirin in cardiovascular disease: An untested hypothesis

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 1, 2006, Pages 4-5

  Hennekens, Charles H ^a,b,d   Hollar, Danielle ^a,b   Baigent, Colin ^c  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPOTHESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; STATISTICAL ANALYSIS; STROKE;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; MALE; RANDOMIZED CONTROLLED TRIALS; SEX FACTORS; TREATMENT OUTCOME;

EID: 30544446630     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0420     Document Type: Review

References (10)

1. Ridker PM et al. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293-1304
2. Eidelman RS et al. (2003) An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163: 2006-2010
3. Levin RI (2005) The puzzle of aspirin and sex. N Engl J Med 352: 1366-1368
4. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106
5. Levin RI et al. (1984) Aspirin inhibits vascular plasminogen activator in vivo: Studies utilizing a new assay to quantify plasminogen activator activity. J Clin Invest 74: 571-580
6. United States Preventive Services Task Force (2002) Aspirin for the primary prevention of cardiovascular events - recommendation and rationale. Ann Intern Med 136: 157-160
7. Pearson TA et al. (2002) American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106: 388-391
8. García Rodríguez LA et al. (2001) Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 52: 563-571
9. Nelson M et al. (2003) Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 20: 897-903
10. Huxley TH (1894) Collected Essays of Thomas Huxley. Discourses Biological and Geological Part Eight New York: Kessinger Publishing